0000000000417261

AUTHOR

Aurélie Joret

showing 3 related works from this author

MOESM1 of Nephrotoxic drug burden among 1001 critically ill patients: impact on acute kidney injury

2019

Additional file 1: Figure S1. Acute kidney injury (AKI) worsening cases and control matching. Table S1. Main characteristics of matched and unmatched patients. Table S2. Relative contribution individual drugs to the difference in nephrotoxic burden experienced by cases and controls.

researchProduct

Nephrotoxic drug burden among 1001 critically ill patients: impact on acute kidney injury.

2019

Abstract Background Nephrotoxic drug prescription may contribute to acute kidney injury (AKI) occurrence and worsening among critically ill patients and thus to associated morbidity and mortality. The objectives of this study were to describe nephrotoxic drug prescription in a large intensive-care unit cohort and, through a case–control study nested in the prospective cohort, to evaluate the link of nephrotoxic prescription burden with AKI. Results Six hundred and seventeen patients (62%) received at least one nephrotoxic drug, among which 303 (30%) received two or more. AKI was observed in 609 patients (61%). A total of 351 patients were considered as cases developing or worsening AKI a gi…

medicine.medical_specialtyIntensive-care units [MeSH]Critical Care and Intensive Care Medicine[SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and NephrologyMESH: Vancomycin03 medical and health sciences0302 clinical medicineMESH: Kidney tubular necrosisRenal insufficiency [MeSH]Internal medicineAnesthesiologyMESH: Renal insufficiencymedicineMESH: Intensive-care unitsKidney tubular necrosisMESH: Diuretics030212 general & internal medicineMedical prescriptionSimplified Acute Physiology ScoreProspective cohort studyMESH: Acutebusiness.industryResearchAcute kidney injurylcsh:Medical emergencies. Critical care. Intensive care. First aidMESH: Aminoglycosides030208 emergency & critical care medicineOdds ratiolcsh:RC86-88.9[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciencesmedicine.diseaseVancomycin [MeSH][SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and NephrologyDiuretics [MeSH]3. Good health[SDV.SP] Life Sciences [q-bio]/Pharmaceutical sciencesContrast media [MeSH]CohortMESH: Contrast mediaAminoglycosides [MeSH]businessAcute [MeSH]Kidney diseaseAnnals of intensive care
researchProduct

Weaning from mechanical ventilation in intensive care units across 50 countries (WEAN SAFE)

2023

Background: Current management practices and outcomes in weaning from invasive mechanical ventilation are poorly understood. We aimed to describe the epidemiology, management, timings, risk for failure, and outcomes of weaning in patients requiring at least 2 days of invasive mechanical ventilation. Methods: WEAN SAFE was an international, multicentre, prospective, observational cohort study done in 481 intensive care units in 50 countries. Eligible participants were older than 16 years, admitted to a participating intensive care unit, and receiving mechanical ventilation for 2 calendar days or longer. We defined weaning initiation as the first attempt to separate a patient from the ventila…

Pulmonary and Respiratory MedicineInternal Medicine SciencesKlinik TıpRESPIRATORY SYSTEMDahili Tıp BilimleriGöğüs Hastalıkları ve AllerjiCLINICAL MEDICINESağlık BilimleriClinical Medicine (MED)TıpSOLUNUM SİSTEMİMechanical ventilationN/AHealth SciencesSettore MED/41 - ANESTESIOLOGIAAkciğer ve Solunum TıbbıMedicineKlinik Tıp (MED)Chest Diseases and AllergyThe Lancet Respiratory Medicine
researchProduct